Scheriproct N is generally used for managing symptoms related to inflammatory or irritative states in the anal region. It is specifically formulated to provide short-term symptomatic assistance by addressing the discomfort, pain, and itching associated with certain anal conditions.

This preparation is generally indicated for the symptomatic relief of conditions characterized by periods of heightened symptoms, specifically haemorrhoids (piles) and pruritus ani (anal itching). The preparation is used in contexts where additional symptomatic support is needed. This treatment is relevant for managing symptoms that interfere with daily comfort and is often used when symptoms intensify.

“It provides support that helps ease the overall symptom burden.”

This combination provides supportive relief during acute or disruptive episodes and may assist with maintaining functional stability.

Quick Fact: Relevant for easing Symptoms related to physical discomfort (pain, itching, inflammation)

Eligibility: Who Can and Cannot Use Scheriproct N?

Regulatory documentation defines strict eligibility criteria based on patient status, age, and local health conditions. The medicine is contraindicated in several groups and requires conditional use in others.

Absolute Contraindications (Must Not Use)

Restricted or Conditional Use

• Pediatric Use: Long-term continuous therapy must be avoided in infants and small children due to the risk of adrenal gland suppression. Safety and efficacy in the general pediatric population are often not established.
• Organ Function: Use requires caution and clinical review in patients with severe hepatic (liver) or renal (kidney) impairment due to the potential for increased systemic exposure of Lidocaine.
• Later Pregnancy/Lactation: Use after the first trimester and during breastfeeding requires careful clinical review, and prolonged use must be avoided.

The documented interaction profile for Scheriproct N is primarily based on the systemic exposure potential of its active components and a specific excipient-based constraint.

Metabolic and Exposure Interactions (Pharmacokinetic)

Co-treatment with strong inhibitors of the Cytochrome P450 3A (CYP3A) enzyme system is expected to inhibit the metabolism of the Fluocortolone component. This pharmacokinetic interaction results in reduced clearance and an increased plasma concentration of the corticosteroid. Medicines explicitly documented as relevant CYP3A inhibitors include cobicistat-containing products and ritonavir. Regulatory bodies define this as an interaction to be avoided, advising that the co-administration should not occur unless the therapeutic benefit formally outweighs the increased documented risk of systemic side-effects.

Additive Effects (Pharmacodynamic)

The local anesthetic, Lidocaine, carries a potential for additive pharmacodynamic effects when co-administered with other local anesthetics or with Class I and Class III antiarrhythmic drugs. This is a known interaction pattern for amide-type local anesthetics. Considering the low systemic exposure achieved via rectal administration, the clinical relevance of these additive effects is generally classified as low.

Excipient-Based Substance Constraint

The formulation contains excipients, such as castor oil and hard fat, which are officially documented to interact with certain materials. These components can reduce the effectiveness of latex products, specifically condoms. No mandatory timing separation rules are documented in the official labeling.

The mechanism of Scheriproct N relies on two distinct and complementary actions: the modulation of the local inflammatory cascade and the immediate blockade of nerve signaling responsible for afferent sensory transmission. The corticosteroid component, Prednisolone Hexanoate, acts as an agonist of the intracellular Glucocorticoid Receptor (GR), initiating a change in gene transcription that suppresses the creation of pro-inflammatory mediators via inhibition of Phospholipase A2 ( PLA2). This physiological cascade helps normalize vascular permeability, leading to decreased capillary permeability and intercellular fluid accumulation and hyperaemia. Concurrently, Cinchocaine Hydrochloride functions as a blocker of neuronal Voltage-Gated Sodium Channels ( VGSC). By obstructing the channel pore, the molecule prevents Na^+ influx and inhibits the propagation of afferent nociceptive and pruritic nerve impulses, resulting in reversible stabilization of the local sensory nerve membrane. This synergistic approach provides simultaneous modulation of sensation (rapid kinetics of VGSC blockade) and inflammatory pathology (kinetics consistent with gene expression modulation).

How to Use Scheriproct N

Scheriproct N is a dual-component preparation administered for localized action via two main routes: topical application to the perianal area and intra-rectal application. The preparation is available as a rectal ointment, which can be applied both externally and internally using the provided applicator, and as suppositories, which are inserted internally.

Official Dosing and Frequency Patterns

The usage pattern typically involves a short-term intensive phase.

For optimal use, the medication is best applied after the bowels have been emptied and the area has been carefully cleaned and dried. Treatment is typically intended for short-term use, often lasting 5 to 7 days. The maximum duration of continuous treatment should not exceed four weeks.

Administration Protocol

After symptoms have subsided, standard instructions involve continuing the application at a reduced frequency (e.g., once daily or every other day) for at least one week to help prevent relapse. The product is generally restricted to use in individuals aged 18 years and over. If a dose is missed, it should be applied when remembered, but users must avoid applying a double dose to compensate for the missed amount.

Research evidence / Overview of studies for Scheriproct N

Evidence for Symptomatic Relief in Acute Anorectal Conditions

This section will summarize the types of clinical studies, including large observational cohorts and regulatory trials, that have evaluated the combination product for its intended use in outcomes related to acute symptoms such as pain, itching, and swelling associated with conditions involving periods of heightened symptoms, like hemorrhoids.

Research has examined the combination of fluocortolone and lidocaine across various designs, including required regulatory trials and large-scale Multicenter Prospective Non-interventional Cohort Studies. These studies was studied for use in research exploring how symptoms change over time when the product was observed in acute conditions. They primarily focused on outcomes related to physical discomfort and outcomes linked to inflammatory or irritative states in adults.

Studies reported how symptoms evolved in the observed populations, measuring changes in both self-reported patient experiences and visible signs. Research highlights changes measured during the study period for symptoms such as pain, itching, and bleeding. Clinical assessments also monitored physical markers, including the recorded size of hemorrhoid nodes and levels of local swelling. This evidence contributes to understanding symptom patterns during the acute treatment phase.

Long-term effects are not fully established for this product. The follow-up durations were limited, as the research was primarily conducted during periods of increased symptom activity and focused on episodes where symptoms become more noticeable. Research has explored short-term symptom changes, but there is limited information for long-term outcomes, as the typical observation periods were only up to 14 days.

Research Context for Managing Postoperative Discomfort

This block will describe the specific research context for using the medicine locally for acute pain following surgical procedures like hemorrhoidectomy, detailing the study designs (e.g., retrospective analyses) and the pain intensity outcomes that were evaluated.

The combination was studied for research exploring outcomes related to physical discomfort immediately following excisional hemorrhoidectomy. The research explored this scenario primarily through Retrospective Comparative Analyses, which were designed to observe the topical combination alongside standard systemic pain management, and supporting Regulatory Data. These studies focused on outcomes related to systemic or functional imbalance caused by acute pain after surgery.

Comparative studies reported patterns of measured pain intensity scores in the early days following the surgical procedure. Pain levels were commonly assessed using standardized scales, and research highlights changes measured during the study period at specific check-up times. These findings describe group patterns, not personal outcomes, as study results reflect the specific conditions under which they were conducted.

The certainty remains low in this specific setting because the direct evidence for the combination was observed in some studies that used retrospective study designs, which may introduce limitations. Furthermore, the follow-up durations were limited, generally to up to 7 days, meaning there is limited information concerning symptom patterns beyond the immediate post-surgical window.

Evidence in Specific Patient Groups

This part of the overview will address which specific subgroups were included in the primary studies—such as the defined adult age range (18 to 65 years)—and will clarify the research landscape for populations where evidence is limited, such as pediatric patients or those with more advanced conditions.

The main body of clinical data and the large observational cohorts was evaluated in a defined adult population, most often cited as 18 to 65 years of age. These populations were typically limited to conditions involving periods of heightened symptoms of Grade 1 or 2 hemorrhoids.

Data for certain groups remain insufficient. For instance, there is limited information concerning the outcomes for older adults, pregnant or breastfeeding women, or pediatric patients. Additionally, the existing studies provide limited evidence for individuals with severe, late-stage hemorrhoidal disease (such as Grade 3 or 4) or those with complex, pre-existing comorbid conditions. Results apply only to the populations studied and do not provide clarity for these specific patient groups.

Key Limitations and Unanswered Research Questions

The evidence quality varies across studies. While some research involves controlled trial settings, the overall published evidence landscape includes a significant reliance on observational study designs and retrospective analyses, which provide context but not the level of certainty that large, double-blind Randomized Controlled Trials (RCTs) offer.

A key limitation is that follow-up durations were limited across the research base, meaning the research provides insight into short-term changes but does not offer a complete picture of the long-term pattern of conditions characterized by fluctuating or episodic manifestations.

Finally, uncertainty remains regarding the long-term management of these conditions, and the outcomes in specific subgroups represent areas where further research would provide greater clarity.

Key Studies & References

1. The effectiveness of combined topical product with fluocortolone pivalate and lidocaine for hemorrhoids: results of a multicenter observational study
2. Acute hemorrhoids | Study 20364 | Bayer - Clinical Trials Explorer
3. A Systematic Review of the Topical Drugs for Post Hemorrhoidectomy Pain

Common questions about Scheriproct N (FAQ)

Q: How quickly does Scheriproct N usually start working?

The product combines components that manage inflammation and pain. The local anesthetic is designed to provide rapid onset of relief for painful and itching symptoms, consistent with its pharmacological function. This speed of action contrasts with the anti-inflammatory effect of the corticosteroid, which takes longer to develop.

Q: Is Scheriproct N suitable for use during pregnancy, according to official guidelines?

Regulatory documents state that Scheriproct N is contraindicated (must not be used) during the first trimester of pregnancy. For the later stages of pregnancy and while breastfeeding, the product information indicates that use requires careful clinical review and that extensive application must be avoided.

Q: What happens if I forget to use Scheripropt N for one application?

According to the official patient instructions, if a dose is missed, it should be applied as soon as the user remembers. However, the official instructions advise avoiding the application of a double dose to compensate for the missed amount.

Q: Are there any known interactions between Scheriproct N and common pain relievers?

Regulatory documents state that formal drug interaction studies have not been performed for Scheriproct N. However, regulatory information notes that co-treatment with strong inhibitors of the CYP3A enzyme system (such as ritonavir) may result in reduced clearance and an increased plasma concentration of the corticosteroid component.

Q: Is it possible to have an allergic reaction to Scheriproct N?

Yes, an allergic reaction is possible. Official safety information lists known hypersensitivity (allergy) to the active ingredients or other components as a reason the medicine must not be used. Allergic skin reactions, such as a rash, have also been documented as an undesirable effect in official safety profiles.

Q: Can Scheriproct N be used by people with diabetes?

The official product documentation does not list diabetes as an absolute contraindication. The potential for systemic absorption means that use in individuals with pre-existing conditions requires caution and clinical review, as systemic effects are a documented risk with prolonged use.

Q: What is the recommended age limit for using Scheriproct N?

Regulatory guidance indicates that use is generally restricted to individuals aged 18 years and over. Furthermore, continuous and long-term therapy is restricted in infants and small children due to the documented risk of adrenal gland suppression.

Q: Does Scheriproct N work on external hemorrhoids or only internal ones?

The product is designed to work on affected areas both externally and internally. The rectal ointment can be applied to the perianal area (external) and can also be inserted into the rectum (internal) using the applicator, while suppositories are specifically for internal rectal use.

Q: Can Scheriproct N be used for anal itching or general skin irritation?

The therapeutic indications for Scheriproct N include the symptomatic relief of pruritus ani, which is itching of the anus. Official documentation does not provide information regarding its use for general, non-specific skin irritation not related to the approved condition.

Q: Is Scheriproct N the same as the regular Scheriproct without the 'N'?

Scheriproct N is the brand name of a preparation containing the active ingredients prednisolone hexanoate and cinchocaine hydrochloride. The ‘N’ designation refers to the specific combination of these two components in the product, which is defined in the regulatory composition section.

Q: Is it normal to feel a slight burning sensation when first applying Scheriproct N?

Yes, a slight burning sensation or irritation is a documented, common initial reaction at the application site. Official safety documents list this as an expected adverse reaction, particularly at the beginning of the treatment period.

Q: Does using Scheriproct N make symptoms disappear permanently?

Scheriproct N is indicated for the short-term symptomatic relief of conditions involving acute discomfort. Its documented research focuses on the changes in symptoms during the acute treatment phase, and official instructions recommend short-term use, typically not exceeding four weeks.

Q: How long after stopping Scheriproct N will the ingredients leave my system?

The product is designed to act locally, meaning only a small fraction of the active ingredients is absorbed into the bloodstream. Systemically, the ingredients are metabolized and eliminated, primarily by the liver, consistent with the pharmacological properties of these types of agents.

Q: Is Scheriproct N manufactured by a well-known pharmaceutical company?

Scheriproct N is manufactured and marketed by the pharmaceutical company that holds the Marketing Authorisation (MA) for the product in the relevant region. This authorisation confirms that the company complies with the documented standards for manufacturing and quality.

Q: Is Scheriproct N available as both a cream and a suppository?

Yes, according to the official product information, Scheriproct N is available in two pharmaceutical forms: a rectal ointment, which is a cream-based preparation, and suppositories, which are designed for internal rectal delivery.

Q: Are there any restrictions on driving or operating machinery while using Scheriproct N?

Regulatory documents explicitly state that Scheriproct N is not expected to have any influence on the ability to drive or use machines.

Q: Are there warnings about using Scheriproct N if you have kidney or liver issues?

Official warnings state that use requires caution and clinical review in patients who have severe hepatic (liver) or renal (kidney) impairment. The requirement for caution is due to the potential for increased systemic exposure of the local anaesthetic component in individuals with severely impaired kidney or liver function.

Q: Does Scheriproct N have a strong odor?

The ointment formulation of Scheriproct N contains a specific perfume oil (Chypre) as an excipient. The official documentation mentions this ingredient as it may cause allergic reactions in sensitive individuals.

Q: Can Scheriproct N affect blood pressure or heart rate?

The product is designed for localized action, but in the case of accidental oral intake (overdose), severe cardiovascular symptoms are the main expected concern, which may include effects on blood pressure or heart rate linked to the local anesthetic component.

Q: Is the potential for systemic absorption of the ingredients a concern?

Yes, systemic absorption is a documented possibility, particularly when the product is used for a prolonged period or extensively over a large area. This is the reason for official warnings regarding HPA-axis suppression (adrenal suppression) and other systemic corticosteroid side effects.

Q: Does Scheriproct N contain any ingredients derived from animal products?

Official excipient lists show that the suppository formulation contains hard fat, and the ointment contains castor oil. The specific origin (animal or vegetable) is often defined by the manufacturer's regulatory filing. Patients with specific dietary concerns may wish to review the full excipient documentation.

Q: Do official patient leaflets warn about rebound effects after stopping the use of Scheriproct N?

While the term 'rebound effect' is not explicitly used in the patient leaflets, the official instructions recommend continuing the application at a reduced frequency for at least one week after symptoms have subsided. This is recommended to help prevent a relapse of the condition.

Q: Can older adults use Scheriproct N safely?

The main clinical data was evaluated in a defined adult population, typically aged 18 to 65 years. Regulatory documents note that there is no specific data available regarding the use of Scheriproct N in the elderly population.

Q: What is the difference in packaging or strength between the cream and the suppositories?

The forms are packaged differently, with the cream supplied in a tube and the suppositories in individual foil wraps. Furthermore, the strength and total quantity of the active ingredients (prednisolone hexanoate and cinchocaine hydrochloride) are different between the ointment and the suppository formulations.

How to Store and Dispose of Scheriproct N

Official regulatory documents detail specific storage and disposal requirements for Scheriproct N to maintain product stability. In all cases, the medicine must be kept out of the sight and reach of children.

Required Storage Conditions

All formulations must not be used after the expiry date.

Disposal Instructions

Unused or expired Scheriproct N must not be thrown away via wastewater or household waste. The official instruction is to ask a pharmacist for guidance on proper disposal to ensure compliance with pharmaceutical waste and environmental regulations.